{
    "output": [
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Announce",
            "Preliminary Q4 and full year 2017 revenue",
            "EVENT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Operate_In",
            "Regenerative medicine segment",
            "SECTOR"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Operate_In",
            "Worldwide distributors",
            "ORG"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Produce",
            "CryoStor \u00ae and HypoThermosol \u00ae biopreservation media products",
            "PRODUCT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Control",
            "Proprietary CryoStor \u00ae and HypoThermosol \u00ae biopreservation media products",
            "PRODUCT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Impact",
            "More than 275 customer clinical applications",
            "CONCEPT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Impact",
            "16 phase 3 clinical trials",
            "EVENT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Raise",
            "Cash balance",
            "FIN_INSTRUMENT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Control",
            "Record revenue",
            "ECON_INDICATOR"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Control",
            "Increased product adoption",
            "CONCEPT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Control",
            "Positive cash flow from operations for the second half of 2017",
            "EVENT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Control",
            "Stronger balance sheet",
            "CONCEPT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Control",
            "Broad adoption of products in the high-growth regenerative medicine market",
            "CONCEPT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Provide",
            "Financial guidance for 2018",
            "EVENT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Expect",
            "Biopreservation media revenue to range between $13.6 million to $14.7 million",
            "ECON_INDICATOR"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Expect",
            "Gross margin to range between 62% to 64%",
            "ECON_INDICATOR"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Expect",
            "Operating expenses to range from $9 million to $9.5 million",
            "ECON_INDICATOR"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Expect",
            "GAAP operating profit on a full year basis",
            "ECON_INDICATOR"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Eliminate",
            "$4.2 million in senior debt",
            "FIN_INSTRUMENT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Add",
            "$5.3 million in cash to our balance sheet",
            "FIN_INSTRUMENT"
        ],
        [
            "BioLife Solutions, Inc.",
            "COMP",
            "Has",
            "Proprietary HypoThermosol \u00ae and CryoStor \u00ae platform of solutions",
            "PRODUCT"
        ]
    ]
}